Nuveen Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $681K | Hold |
80,443
| – | – | ﹤0.01% | 2875 |
|
|
2024
Q3 | $932K | Hold |
80,443
| – | – | ﹤0.01% | 2795 |
|
|
2024
Q2 | $948K | Buy |
80,443
+9,376
| +13% | +$110K | ﹤0.01% | 2750 |
|
|
2024
Q1 | $843K | Hold |
71,067
| – | – | ﹤0.01% | 2767 |
|
|
2023
Q4 | $871K | Buy |
71,067
+10,115
| +17% | +$124K | ﹤0.01% | 2798 |
|
|
2023
Q3 | $587K | Sell |
60,952
-831
| -1% | -$8K | ﹤0.01% | 2788 |
|
|
2023
Q2 | $556K | Hold |
61,783
| – | – | ﹤0.01% | 2880 |
|
|
2023
Q1 | $485K | Sell |
61,783
-7,163
| -10% | -$56.2K | ﹤0.01% | 2813 |
|
|
2022
Q4 | $982K | Sell |
68,946
-10,832
| -14% | -$154K | ﹤0.01% | 2683 |
|
|
2022
Q3 | $1.16M | Buy |
79,778
+535
| +0.7% | +$7.77K | ﹤0.01% | 2679 |
|
|
2022
Q2 | $779K | Buy |
79,243
+15,338
| +24% | +$151K | ﹤0.01% | 2895 |
|
|
2022
Q1 | $962K | Buy |
63,905
+805
| +1% | +$12.1K | ﹤0.01% | 2828 |
|
|
2021
Q4 | $796K | Sell |
63,100
-59,022
| -48% | -$745K | ﹤0.01% | 2929 |
|
|
2021
Q3 | $2.35M | Sell |
122,122
-237
| -0.2% | -$4.56K | ﹤0.01% | 2597 |
|
|
2021
Q2 | $2.93M | Buy |
122,359
+39,269
| +47% | +$941K | ﹤0.01% | 2530 |
|
|
2021
Q1 | $1.3M | Sell |
83,090
-748
| -0.9% | -$11.7K | ﹤0.01% | 2802 |
|
|
2020
Q4 | $1.59M | Sell |
83,838
-26,953
| -24% | -$512K | ﹤0.01% | 2620 |
|
|
2020
Q3 | $1.4M | Buy |
110,791
+256
| +0.2% | +$3.22K | ﹤0.01% | 2535 |
|
|
2020
Q2 | $1.34M | Buy |
110,535
+53,863
| +95% | +$652K | ﹤0.01% | 2496 |
|
|
2020
Q1 | $433K | Buy |
56,672
+17,193
| +44% | +$131K | ﹤0.01% | 2814 |
|
|
2019
Q4 | $703K | Buy |
39,479
+7,279
| +23% | +$130K | ﹤0.01% | 2812 |
|
|
2019
Q3 | $374K | Sell |
32,200
-29,706
| -48% | -$345K | ﹤0.01% | 3019 |
|
|
2019
Q2 | $1.37M | Buy |
+61,906
| New | +$1.37M | ﹤0.01% | 2609 |
|